SCHEMBL509265

SCHEMBL509265

CCC(NN)C(=O)O

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15764299 1.00
Hydrochloric Acid SCHEMBL899426 0.97
SCHEMBL27398886 0.80
SCHEMBL14762390 0.80 SLC1A2 (0.55)
SCHEMBL25695753 0.79
SCHEMBL29087648 0.79
SCHEMBL14110644 0.78 KDM4E (0.41)
SCHEMBL112740 0.78 KDM4E (0.41)
SCHEMBL30545241 0.77 GNPAT (0.53)
SCHEMBL4605970 0.77 GNPAT (0.53)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 66 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250208137-A1 COMPOUNDS FOR THE DETECTION AND INHIBITION OF COAGULATION PROTEASES CAMBRIDGE ENTERPRISE LIMITED (GB) 2025-06-26 US claimed
EP-4493273-A1 COMPOUNDS FOR THE DETECTION AND INHIBITION OF COAGULATION PROTEASES Politechnika Wroclawska (PL) 2025-01-22 EP claimed
WO-2023175356-A1 COMPOUNDS FOR THE DETECTION AND INHIBITION OF COAGULATION PROTEASES POLITECHNIKA WROCLAWSKA (PL) 2023-09-21 WO claimed
CN-109897001-A A kind of ester type compound, preparation method and application replacing diazanyl containing two 南京农业大学 2019-06-18 CN claimed
EP-2628741-A2 NOVEL COMPOUND OF A REVERSE-TURN MIMETIC AND A PRODUCTION METHOD AND USE THEREFOR JW Pharmaceutical Corporation (KR) 2013-08-21 EP claimed
US-20130196972-A1 NOVEL COMPOUND OF A REVERSE-TURN MIMETIC AND A PRODUCTION METHOD AND USE THEREFOR JW PHARMACEUTICAL CORPORATION (KR) 2013-08-01 US claimed
EP-2419430-A2 NOVEL COMPOUNDS OF REVERSE-TURN MIMETICS, METHOD FOR MANUFACTURING THE SAME AND USE THEREOF JW Pharmaceutical Corporation (KR) 2012-02-22 EP claimed
US-20100267672-A1 NOVEL COMPOUNDS OF REVERSE-TURN MIMETICS, METHOD FOR MANUFACTURING THE SAME AND USE THEREOF CHOONGWAE PHARMA CORPORATION (KR) 2010-10-21 US claimed
WO-2010120112-A2 NOVEL COMPOUNDS OF REVERSE-TURN MIMETICS, METHOD FOR MANUFACTURING THE SAME AND USE THEREOF CHOONGWAE PHARMA CORPORATION (KR) 2010-10-21 WO claimed
US-20070259406-A1 Antimicrobial Compounds UMC UTRECHT HOLDING B.V. (NL) 2007-11-08 US claimed
EP-1664101-A2 EPILANCIN 15X LANTIBIOTIC UMC Utrecht Holding B.V. (NL) 2006-06-07 EP claimed
WO-2005023852-A2 EPILANCIN 15X LANTIBIOTIC UMC UTRECHT HOLDING B.V. (NL) 2005-03-17 WO claimed
US-20250208137-A1 COMPOUNDS FOR THE DETECTION AND INHIBITION OF COAGULATION PROTEASES CAMBRIDGE ENTERPRISE LIMITED (GB) 2025-06-26 US disclosed
EP-4493273-A1 COMPOUNDS FOR THE DETECTION AND INHIBITION OF COAGULATION PROTEASES Politechnika Wroclawska (PL) 2025-01-22 EP disclosed
WO-2023175356-A1 COMPOUNDS FOR THE DETECTION AND INHIBITION OF COAGULATION PROTEASES POLITECHNIKA WROCLAWSKA (PL) 2023-09-21 WO disclosed
WO-2023102239-A1 THERAPEUTIC COMPOUNDS FOR HIV VIRUS INFECTION GILEAD SCIENCES, INC. (US) 2023-06-08 WO disclosed
WO-2002085860-A1 PYRAZOLE DERIVATIVES FOR TREATING HIV PFIZER LIMITED (GB) 2002-10-31 WO disclosed
EP-1171405-A1 FUNCTIONALISED SOLID SUPPORT FOR ALPHA-OXOALDEHYDE SYNTHESIS INSTITUT PASTEUR DE LILLE (FR) 2002-01-16 EP disclosed
WO-2000064843-A1 FUNCTIONALISED SOLID SUPPORT FOR ALPHA-OXOALDEHYDE SYNTHESIS INSTITUT PASTEUR DE LILLE (FR) 2000-11-02 WO disclosed
US-6124290-A TREATING BACTERIAL INFECTIONS GRUENENTHAL GMBH (DE) 2000-09-26 US disclosed